Advaite

Advaite Founder and Chief Scientific officer, Sandeep Jain, MD, and Christine Mun BS are authors on a publication that points to the potential of Neutrophil-associated proteins (Interlukin-8, or LIGHT/TNFSF14) to serve as biomarkers and heparin eye drops as treatment for ocular GVHD. These biomarkers and therapeutics are being developed by Advaite for diagnosing and treating ocular GVHD.

Neutrophil extracellular traps (NETs) contribute to pathological changes of ocular graft-vs.-host disease (oGVHD) dry eye: Implications for novel biomarkers and therapeutic strategies To investigate the role of neutrophil extracellular traps (NETs) and NET-associated proteins in the pathogenesis of oGVHD and whether dismantling of N…

Advaite has entered into an exclusive license option agreement with the George Washington University with respect to the intellectual property of a novel AMES Negative HDAC6 inhibitor. Histone Deacetylases modulate a multitude of cellular processes and are part of the regulation of cellular pathways involved in anti-tumor immunologic responses.

Advaite Inc. Enters into Exclusive License Option Agreement with the George Washington University for Novel AMES Negative HDAC6 Inhibitor Technology /PRNewswire/ -- Advaite Inc., a Chicago, IL based oncology-focused biotech company developing novel therapeutics and diagnostics to help patients suffering...

Advaite Founder and Chief Scientific officer, Sandeep Jain, MD, and Christine Mun BS, presented clinical data in a Special Interest Group talk and a poster highlighting the potential of LIGHT/TNFSF14 protein (ADV200) to serve as a diagnostic and monitoring biomarker at the Association for Research in Vision and Ophthalmology (ARVO) 2019 Annual Meeting, held on April 28 – May 2, 2019, in Vancouver, Canada. The results showed that LIGHT/TNFSF14 protein had a specificity of over 90% in diagnosing ocular GVHD. In contrast, MMP-9 test (InflammaDry) had a specificity of only 9%.

Advaite Chief Scientific officer, Sandeep Jain, MD, presented pre-clinical and clinical data regarding heparin eye drops (ADV100) at the International Society for Eye Research (ISER) biennial meeting held in Belfast, Ireland on September 9 - 13, 2018.

Advaite Founder and Chief Scientific officer, Sandeep Jain, MD, presented preclinical data in a poster highlighting the potential efficacy of sub-anticoagulant dose heparin (ADV100) at the Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting, held April 29 – May 3, 2018, in Honolulu, Hawaii. The results highlighted the anti-inflammatory, immunosuppressive and antifibrotic actions of heparin (100 IU/ml) using preclinical in-vitro and in-vivo models.

ADVAITE Founder and Chief Scientific Officer Dr. Sandeep Jain featured in UIC NEWS

Inventor of the Year: Sandeep Jain | UIC Today Sandeep Jain is amongst the few clinical scientists in the field who have taken their research discovery from laboratory to the clinic and converted them to new therapies.